Key Highlights

  • Net ZEVASKYN Revenue reached $11.4 million, up 31 percent from $8.7 million in the first quarter, though revenue of $11.4 million missed the $12.2 million estimate by 7.01 percent.
  • Adjusted EPS of negative $0.35 missed the negative $0.23 estimate by 52.17 percent, while 12 patients have now been treated with ZEVASKYN since launch, including five in the second quarter.
  • CMS granted ZEVASKYN New Technology Add-on Payment status effective October 1, 2026, one of only three approvals out of 15 applications submitted for fiscal year 2027.
  • The company activated its seventh qualified treatment center with the addition of Cincinnati Children's Hospital, with roughly 40 percent of the addressable patient population now having in-state access to a center.

Revenue Grows Despite Two Non-Billable Manufacturing Batches

Abeona Therapeutics Inc (NASDAQ:ABEO), a commercial-stage biopharmaceutical company Marketing ZEVASKYN, a surgically applied autologous cell therapy for recessive dystrophic epidermolysis bullosa, reported second-quarter net revenue of $11.4 million, up 31 percent from the first quarter, even as revenue was not recognized for two of the five patients treated during the quarter. One case involved a manufacturing batch with cell Yield below the company's revenue recognition threshold, while a separate batch failed an identity specification test unrelated to safety or potency, with management noting both patients still received treatment despite the company forgoing revenue on those cases.

Management said the low-yield event represents a low-probability occurrence given the company's limited but growing manufacturing dataset, with commercial-setting yields, averaging roughly nine sheets per batch, actually outperforming the company's Phase 3 clinical trial experience, which averaged closer to five sheets per patient. The specification test failure stemmed from thresholds set using a small pre-commercial sample size during the company's Biologics license application review, and the company is now working with the FDA to revisit those specifications using its growing real-world manufacturing data.

Treatment Center Network Reaches Seven Sites, Unlocking Broader Patient Access

The company activated Cincinnati Children's Hospital, one of the largest epidermolysis bullosa treatment centers in the country, bringing its qualified treatment center network to seven sites and meeting its stated goal for the year. Based on claims analysis, approximately 40 percent of the addressable patient population now has in-state access to a treatment center, though management emphasized the company's centers also serve a substantial number of patients traveling from out of state given the specialized nature of care required.

Execution timelines between site activation and first patient treatment have varied considerably, with Children's Hospital of Philadelphia completing its first treatment within roughly two months of activation, while other centers have taken up to 12 months without yet treating a patient. Management attributed this variability to the operationally complex, multi-stakeholder coordination required given the therapy's 84-hour shelf life, along with site-specific factors including payer mix, prior authorization timelines, and hospital administrative processes.

Medicare Add-On Payment Approval Provides a Reimbursement Validation Signal

CMS granted ZEVASKYN New Technology Add-on Payment status effective October 1, 2026, one of only three approvals among 15 applications submitted under the traditional pathway for fiscal year 2027, providing hospitals supplemental reimbursement for the therapy during inpatient stays. While Medicare represents only about 10 percent of the overall RDEB payer mix, management said the approval carries a broader halo effect, providing external validation that may ease reimbursement negotiations and prior authorization discussions with other payer types beyond the direct financial benefit to treating hospitals.

The company also disclosed that two scheduled patient biopsies were canceled at the last minute during the quarter due to unexpected declines in patient health, a dynamic management said is difficult to predict or mitigate once it occurs so close to a scheduled procedure, since replacing a canceled slot on short notice is not feasible given the extensive advance coordination required. Executives said expanding the pool of patients entering the treatment pipeline at any given time is the primary strategy for offsetting this kind of unavoidable attrition.

Reporting Changes Aim to Improve Transparency as Launch Enters Its Second Year

Management announced a change to future reporting practices, committing to anchor quarterly disclosures solely around completed patient treatments and net revenue recognized within the reported quarter, rather than leading indicators such as scheduled biopsies, which the company said have proven to have limited predictive value given the launch's operational complexity. Research and Development expenses fell to $5 million from $9.6 million in the prior quarter, which had included a one-time $7 million upfront licensing payment, while the company ended the quarter with $146.8 million in cash, cash equivalents, and short-term investments. The company's path toward sustained Cash Flow positivity will depend on maintaining a consistent cadence of patient treatments as gross margins are expected to reach 85 to 90 percent once the Business achieves full operating capacity, a milestone that in turn depends on newer treatment centers reaching the roughly one-patient-per-month cadence management has observed at its most established sites.